Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Want to see LSTA full AI Analyst Report?
LSTA Stock Chart & Stats
$1.95
-$0.01(-0.27%)
At close: 4:00 PM EST
$1.95
-$0.01(-0.27%)
Day’s Range― - ―
52-Week Range$1.81 - $5.07
Previous CloseN/A
Volume45.87K
Average Volume (3M)34.52K
Market Cap
$31.60M
Enterprise Value$18.99M
Total Cash (Recent Filing)$13.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding9,106,391
10 Day Avg. Volume57,561
30 Day Avg. Volume34,515
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.09
Price to Sales (P/S)95.05
P/FCF Ratio-1.01
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue111.73
Enterprise Value/Gross Profit113.06
Enterprise Value/Ebitda-1.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEncouraging preliminary results from Cohort B of the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma.
Clinical TrialsEnrollment in the 1L cohort was completed nearly 6 months ahead of initial projections, accelerating the anticipated topline data readout to 4Q25.
Financial PerformanceLisata announced 2Q25 financial results, posting EPS of ($0.54) compared to our estimate of ($0.66) and consensus of ($0.65).
Bears Say
EarningsThe company ended the quarter with approximately $22 million in cash, which management believes can cover expenses for all ongoing and proposed trials with runway into 4Q26.
Lisata Therapeutics News
LSTA FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was $1.81 and its highest was $5.07 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is $31.60M.
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 52 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on May 07, 2026. The company reported -$0.498 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.498.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Overvalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics pays a Notavailable dividend of $0.31 which represents an annual dividend yield of N/A. See more information on Lisata Therapeutics dividends here
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 9,106,391 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.498 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.92%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Currently, no hedge funds are holding shares in LSTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lisata Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.50%
12-Months-Change
Fundamentals
Return on Equity
-101.90%
Trailing 12-Months
Asset Growth
-51.49%
Trailing 12-Months
Company Description
Lisata Therapeutics
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
LSTA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
―
Aptevo Therapeutics
―
Citius Pharmaceuticals
―
Processa Pharmaceuticals
―
Apollomics
―
Ownership Overview
10.45% Insiders
3.61% Mutual Funds
3.65% Other Institutional Investors
79.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---